Article
Cardiac & Cardiovascular Systems
Steffen D. Kriechbaum, Judith Birmes, Christoph B. Wiedenroth, Miriam S. D. Adameit, Dimitri Gruen, J. Vietheer, Manuel J. Richter, Stefan Guth, Fritz C. Roller, Matthias Rademann, Ulrich Fischer-Rasokat, Andreas Rolf, Christoph Liebetrau, Christian W. Hamm, Till Keller, Andreas J. Rieth
Summary: This study investigated the dynamics of right atrial pressure and mid-regional pro-atrial natriuretic peptide during physical exercise in CTEPH patients and found that these parameters may serve as indicators of exercise-dependent atrial stress and right heart failure.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Medicine, General & Internal
Rita Indirli, Alessandra Bandera, Luca Valenti, Ferruccio Ceriotti, Adriana Di Modugno, Mauro Tettamanti, Roberta Gualtierotti, Flora Peyvandi, Nicola Montano, Francesco Blasi, Giorgio Costantino, Veronica Resi, Emanuela Orsi, Maura Arosio, Giovanna Mantovani, Emanuele Ferrante
Summary: This study assessed the predictive value of copeptin and MR-proADM for in-hospital outcomes in COVID-19 patients. The results showed that both copeptin and MR-proADM could predict mortality, complications, and length of stay. They may be useful for early risk stratification and care intensification in COVID-19 patients.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Cardiac & Cardiovascular Systems
Karin Hochrainer, Wei Yang
Summary: Stroke proteomics studies in both animal and human specimens are comprehensively reviewed in this article, with discussions on the limitations, challenges, and future perspectives in the field. The authors also provide a unique resource by presenting extensive lists of proteins identified as altered by stroke in proteomic studies, and perform post-analysis to reveal stroke-related cellular processes and pathways.
CIRCULATION RESEARCH
(2022)
Article
Critical Care Medicine
C. de Roquetaillade, C. Dupuis, V Faivre, A. C. Lukaszewicz, C. Brumpt, D. Payen
Summary: mHLA-DR is downregulated in ICU patients after admission, and persistent low mHLA-DR expression is associated with subsequent ICU-acquired infections. The combination of multiple markers can provide better evaluation performance.
ANNALS OF INTENSIVE CARE
(2022)
Review
Biochemistry & Molecular Biology
Lazzaro di Biase, Adriano Bonura, Pasquale Maria Pecoraro, Simona Paola Carbone, Vincenzo Di Lazzaro
Summary: Stroke, a complex and heterogeneous disease, poses challenges for early diagnosis and treatment due to the lack of specific diagnostic biomarkers. This review identifies four promising biomarkers for early diagnosis, differentiation between ischemic and hemorrhagic stroke, and prediction of hemorrhagic transformation. Integration of these biomarkers could significantly improve stroke patients' detection and treatment. However, further research and validation are needed to demonstrate their clinical utility in routine stroke treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medical Laboratory Technology
Jean Alex Matos Ribeiro, Luisa Fernanda Garcia-Salazar, Cassia Regina Saade-Pacheco, Erika Shirley Moreira Silva, Simone Garcia Oliveira, Ana Flavia Silveira, Adriana Sanches Garcia-Araujo, Thiago Luiz Russo
Summary: By synthesizing the potential predictive molecular biomarkers for motor recovery following acute hemorrhagic stroke, it was found that 61 independent prognostic molecular biomarkers could predict motor functional recovery. The results of this study suggest that these biomarkers assessed in the acute phase are valuable for predicting motor functional recovery.
CLINICA CHIMICA ACTA
(2021)
Article
Clinical Neurology
Sauson Soldozy, Kaan Yagmurlu, Pedro Norat, Mazin Elsarrag, John Costello, Faraz Farzad, Jennifer D. Sokolowski, Khadijeh A. Sharifi, Turki Elarjani, Joshua Burks, Petr Tvrdik, Mark E. Shaffrey, Min S. Park, Robert M. Starke, Errol Gordon, M. Yashar S. Kalani
Summary: This study systematically reviewed the usefulness of serum biomarkers in predicting long-term outcome after ischemic stroke (IS). The analysis identified C-reactive protein, albumin, copeptin, and D-dimer to be significantly associated with long-term outcome. These serum biomarkers, combined with imaging biomarkers and used in artificial intelligence algorithms, can provide refined predictive outcomes.
WORLD NEUROSURGERY
(2022)
Article
Medical Laboratory Technology
Yin Liu, Ruizhi Wang, Jing Cheng, Jianfeng Wu, Shihong Zhang
Summary: The study demonstrated that the D7-PCT/mHLA-DR ratio had better predictive value for 28-day mortality in septic patients. Combining pro-inflammatory and immunosuppression biomarkers could improve prognostic accuracy in sepsis.
CLINICA CHIMICA ACTA
(2021)
Review
Biochemistry & Molecular Biology
Lidia Wlodarczyk, Rafal Szelenberger, Natalia Cichon, Joanna Saluk-Bijak, Michal Bijak, Elzbieta Miller
Summary: Key issues affecting stroke rehabilitation clinical practice include a patient's medical history, stroke experience, recovery potential, and therapy selection. Finding biomarkers that predict brain recovery potential in stroke patients is crucial. Utilizing biomarkers for personalized medicine development and enhancing brain neuroplasticity are important in stroke rehabilitation and other central nervous system diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Zhengbao Zhu, Daoxia Guo, Kaixin Zhang, Pinni Yang, Yiming Jia, Mengyao Shi, Yanbo Peng, Jing Chen, Aili Wang, Tan Xu, Yonghong Zhang, Jiang He
Summary: Plasma osteoprotegerin is associated with poor prognosis of ischemic stroke. High levels of plasma osteoprotegerin are associated with increased risk of death and major disability. Genetically determined high plasma osteoprotegerin is associated with an increased risk of primary outcome.
Article
Clinical Neurology
Jiejie Li, Yuesong Pan, Jie Xu, Shiyu Li, Mengxing Wang, Kehua Quan, Xia Meng, Hao Li, Jinxi Lin, Yilong Wang, Xingquan Zhao, Liping Liu, Yongjun Wang
Summary: Residual inflammatory risk only may predict recurrent stroke and poor functional outcome in patients with acute ischemic stroke or transient ischemic attack, especially in those with large-artery atherosclerosis.
Review
Biochemistry & Molecular Biology
Codrin-Constantin Burlacu, Daniela Ciobanu, Andrei-Vlad Badulescu, Vlad-Florin Chelaru, Andrei-Otto Mitre, Bogdan Capitanescu, Dirk M. Hermann, Aurel Popa-Wagner
Summary: Stroke is the second leading cause of death and disability, with limited therapeutic strategies. Blood-based biomarkers, such as microRNAs and exosomes, are recognized as useful tools to predict prognosis in patients with stroke. This systematic review identified 72 circulating biomarkers with prognostic value in stroke recovery, including 68 miRNAs predictive for motor recovery and seven biomarkers predictive for cognitive recovery. The most significant correlations were found with miR-21, miR-29b, miR-125b-5p, miR-126, and miR-335. Serum miR-9 and neutrophil miR-29b were identified as promising biomarkers for further studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Edward R. Bader, Tiberiu A. Pana, Raphae S. Barlas, Anthony K. Metcalf, John F. Potter, Phyo K. Myint
Summary: This study investigates the association between admission inflammatory biomarkers and adverse outcomes in spontaneous intracerebral hemorrhage (ICH) using a stroke register in the United Kingdom. The results show that elevated inflammatory biomarkers are associated with poor outcomes in ICH, highlighting the importance of inflammation in this condition.
JOURNAL OF NEUROLOGY
(2022)
Article
Immunology
Bo Peng, Min Yang, Quan Zhuang, Junhui Li, Pengpeng Zhang, Hong Liu, Ke Cheng, Yingzi Ming
Summary: This study standardized the measurement of nCD64 and mHLA-DR using MESF, and evaluated their role in immune monitoring for kidney transplant recipients (KTRs) with infection. The standardized values of nCD64 and mHLA-DR showed good diagnostic performance for infection and sepsis, respectively, and could contribute to individualized treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Jiejie Li, Yuesong Pan, Mengxing Wang, Xia Meng, Jinxi Lin, Zixiao Li, Hao Li, Yilong Wang, Xingquan Zhao, Liping Liu, Yongjun Wang
Summary: This study found that elevated levels of high-sensitivity C-reactive protein (hsCRP) were associated with an increased risk of recurrent stroke. The association was more apparent in patients with minor stroke or transient ischemic attack (TIA), especially in the large-artery atherosclerosis subtype. However, for patients with non-minor stroke, the association disappeared.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Robert Fleischmann, Tina Andrasch, Sina Warwas, Rhina Kunz, Stefan Gross, Carl Witt, Johanna Ruhnau, Antje Vogelgesang, Lena Ulm, Annerose Mengel, Bettina von Sarnowski
Summary: This study identified risk factors for the incidence and duration of post-stroke delirium using high-frequency screening. Age, gender, pain, urinary catheter, and post-stroke infection were found to be significant predictors. Insular and basal ganglia lesions also increased the risk of post-stroke delirium.
INTERNATIONAL JOURNAL OF STROKE
(2023)
Review
Clinical Neurology
Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite
Summary: This study examined the relationship between autoantibody levels and disease activity in patients with myasthenia gravis (MG). The results indicated a potential positive correlation, which could have clinical implications in guiding treatment decisions. However, due to limited and variable evidence, routine clinical use of autoantibody level testing is not currently recommended.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Lisa Schwarz, Nilufar Akbari, Harald Pruss, Andreas Meisel, Franziska Scheibe
Summary: This retrospective single-center study investigated the clinical characteristics, treatments, prognostic factors, and neurological outcome of patients with severe autoimmune encephalitis (AE) in the intensive care unit (ICU). The findings suggest that treatment-refractory AE patients with neuronal surface antibodies (nsAb) can achieve similarly good outcomes after plasma cell-depleting escalation therapy as patients already responding to standard first- and/or second-line therapies.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Frauke Stascheit, Ulrike Grittner, Sarah Hoffmann, Philipp Mergenthaler, Michael Schroeter, Tobias Ruck, Mark Pawlitzki, Franz Blaes, Julia Kaiser, Ulrike Schara, Adela Della-Marina, Andrea Thieme, Tim Hagenacker, Christian Jacobi, Benjamin Berger, Peter P. Urban, Karl Christian Knop, Berthold Schalke, De-Hyung Lee, Petra Kalischewski, Heinz Wiendl, Andreas Meisel
Summary: Current immunosuppressive therapy (IST) increases the severity of COVID-19 in patients with myasthenia gravis, but it does not increase the risk of SARS-CoV-2 infection. Therefore, effective strategies should be implemented to prevent COVID-19 in this high-risk group.
JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Sarah Hoffmann, Werner Stenzel, Andreas Meisel
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Sarah Hoffmann, Patrick Waters, Leslie Jacobson, Markus Schuelke, Werner Stenzel, Tobias Ruck, Sophie Lehnerer, Frauke Stascheit, Corinna Preusse, Andreas Meisel
Summary: Autoantibody testing is essential for autoimmune myasthenia gravis diagnosis, but about 15% of patients still show negative results (seronegative MG). This study examined the prevalence of clustered AChR, MuSK, and LRP4 autoantibodies in a large German cohort of seronegative MG patients using a live cell-based assay. Out of 67 SNMG patients, 4.5% had clustered AChR autoantibodies, with two patients showing binding to both adult and fetal AChR. None of the patients tested positive for MuSK or LRP4 autoantibodies. Clinical characteristics were similar between patients with and without clustered AChR autoantibodies. Comparisons with a national MG registry showed broad similarities among seronegative MG patients in both cohorts.
NEUROMUSCULAR DISORDERS
(2023)
Article
Medicine, General & Internal
Sarah Dewilde, Glenn Philips, Sandra Paci, Jon Beauchamp, Silvia Chiroli, Casey Quinn, Laura Day, Mark Larkin, Jacqueline Palace, Sonia Berrih-Aknin, Kristl G. Claeys, Srikanth Muppidi, Renato Mantegazza, Francesco Sacca, Andreas Meisel, Guillaume Bassez, Hiroyuki Murai, M. F. Janssen
Summary: This study aims to explore the impact of myasthenia gravis (MG) on health-related quality of life (HRQoL) from the perspective of patients. The results showed that MG significantly affects patients' daily activities, anxiety and depression, fatigue, breathing, and vision. The impact of the disease becomes more severe with increasing disease severity.
Article
Clinical Neurology
Frauke Stascheit, Annette Aigner, Philipp Mergenthaler, Benjamin Hotter, Sarah Hoffmann, Sophie Lehnerer, Christian Meisel, Andreas Meisel
Summary: This study aimed to evaluate the association between Nfl and neuromuscular destruction and disease severity in MG patients. Serum samples from MG patients and controls were analyzed and compared. The results showed that sNfl levels were higher in MG patients compared to controls, but were not consistently associated with disease severity. Thus, sNfl is not a suitable biomarker for monitoring individual disease progression in MG patients.
FRONTIERS IN NEUROLOGY
(2023)
Article
Immunology
Dirk Reinhold, Vadim Farztdinov, Yan Yan, Christian Meisel, Henrik Sadlowski, Joachim Kuehn, Frank H. Perschel, Matthias Endres, Emrah Duezel, Stefan Vielhaber, Karina Guttek, Alexander Goihl, Morten Veno, Bianca Teegen, Winfried Stoecker, Paula Stubbemann, Florian Kurth, Leif E. Sander, Markus Ralser, Carolin Otto, Simon Streit, Sven Jarius, Klemens Ruprecht, Helena Radbruch, Jorgen Kjems, Michael Muelleder, Frank Heppner, Peter Koertvelyessy
Summary: Patients with COVID-19 may experience various neurological symptoms, but the role of the central nervous system (CNS) in COVID-19 is still unclear. The inflammatory response in the cerebrospinal fluid (CSF) of COVID-19 patients was studied, and it was found that there were attenuated inflammatory changes compared to patients with herpes simplex virus encephalitis (HSVE). The inflammatory mediators in the CSF of COVID-19 patients were likely derived from the systemic circulation rather than produced within the CNS. Further investigation is needed to understand the relevance of blood-derived mediators of inflammation in the CSF for neurological COVID-19 and post-COVID-19 symptoms.
JOURNAL OF NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Thomas Meyer, Peggy Schumann, Patrick Weydt, Susanne Petri, Yasemin Koc, Susanne Spittel, Sarah Bernsen, Rene Guenther, Jochen H. Weishaupt, Marie Dreger, Felix Kolzarek, Dagmar Kettemann, Jenny Norden, Matthias Boentert, Maximilian Vidovic, Christian Meisel, Christoph Muench, Andre Maier, Peter Koertvelyessy
Summary: This study assessed the changes in neurofilament light chain (NfL) levels in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1-ALS) during treatment with tofersen. The results showed a decrease in NfL levels in all patients treated with tofersen, suggesting its potential disease-modifying activity.
Article
Clinical Neurology
Antje Mevius, Lars Joeres, Jutta Biskup, Tanja Heidbrede, Milada Mahic, Thomas Wilke, Ulf Maywald, Sophie Lehnerer, Andreas Meisel
Summary: The aim of this retrospective cohort study was to estimate the prevalence and incidence of myasthenia gravis (MG) in Germany and understand the burden of disease and treatment patterns. The study found that the prevalence of MG in Germany was approximately 39.3/10 0,0 0 0, and the incidence in 2019 was 4.6/10 0,0 0 0. A significant proportion of MG patients remained untreated, and many patients experienced exacerbations or myasthenic crises. MG was associated with higher mortality compared to the general non-MG population.
NEUROMUSCULAR DISORDERS
(2023)
Article
Medicine, General & Internal
Sonia Berrih-Aknin, Jacqueline Palace, Andreas Meisel, Kristl G. Claeys, Srikanth Muppidi, Francesco Sacca, Fatemeh Amini, Mark Larkin, Casey Quinn, Jon Beauchamp, Glenn Philips, Femke De Ruyck, Joyce Ramirez, Sandra Paci
Summary: This study aims to explore the impact of myasthenia gravis (MG) in the real world from a patient perspective. The study included MG patients from different countries and found that despite current treatments, patients still experience a significant burden.
Article
Medicine, Research & Experimental
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Raeuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stuehler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck
Summary: Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis. A combined proteomics and metabolomics approach was used to study a cohort of MG patients treated with eculizumab or azathioprine, as well as treatment-naive patients. Eculizumab was found to modulate the serum proteometabolome, affecting pathways related to oxidative stress, MAP kinase signaling, and lipid metabolism, particularly arachidonic acid signaling.
Article
Multidisciplinary Sciences
Kathrin Goedde, Hella Fuegemann, Ute Goerling, Ulrike Grittner, Raphael Kohl, Andreas Meisel, Thomas Reinhold, Susanne J. Schnitzer, P. Markus Deckert, Nikolaj Frost, Stephan Schreiber, Nina Rieckmann, Christine Holmberg
Summary: This feasibility study aims to evaluate a patient-oriented navigation model that integrates data about barriers to care, vulnerable patient populations, and existing support services. The study consists of two randomized controlled trials and observational cohorts, with the intervention group receiving support from personal navigators for 12 months while the control group receives a brochure with regional support offers. The feasibility of the navigation model is evaluated in terms of acceptance, demand, practicality, and efficacy.